Your browser doesn't support javascript.
loading
Pathological autoantibody internalisation in myositis.
Pinal-Fernandez, Iago; Muñoz-Braceras, Sandra; Casal-Dominguez, Maria; Pak, Katherine; Torres-Ruiz, Jiram; Musai, Jon; Dell'Orso, Stefania; Naz, Faiza; Islam, Shamima; Gutierrez-Cruz, Gustavo; Cano, Maria Dolores; Matas-Garcia, Ana; Padrosa, Joan; Tobias-Baraja, Ester; Garrabou, Gloria; Aldecoa, Iban; Espinosa, Gerard; Simeon-Aznar, Carmen Pilar; Guillen-Del-Castillo, Alfredo; Gil-Vila, Albert; Trallero-Araguás, Ernesto; Christopher-Stine, Lisa; Lloyd, Thomas E; Liewluck, Teerin; Naddaf, Elie; Stenzel, Werner; Greenberg, Steven A; Grau, Josep Maria; Selva-O'Callaghan, Albert; Milisenda, Jose Cesar; Mammen, Andrew Lee.
Afiliación
  • Pinal-Fernandez I; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov.
  • Muñoz-Braceras S; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Casal-Dominguez M; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Pak K; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Torres-Ruiz J; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Musai J; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Dell'Orso S; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Naz F; Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Islam S; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Gutierrez-Cruz G; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Cano MD; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Matas-Garcia A; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Padrosa J; Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Tobias-Baraja E; Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
  • Garrabou G; Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
  • Aldecoa I; Barcelona University, Barcelona, Spain.
  • Espinosa G; CIBERER and IDIBAPS, Barcelona, Spain.
  • Simeon-Aznar CP; CIBERER and IDIBAPS, Barcelona, Spain.
  • Guillen-Del-Castillo A; Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
  • Gil-Vila A; Barcelona University, Barcelona, Spain.
  • Trallero-Araguás E; CIBERER and IDIBAPS, Barcelona, Spain.
  • Christopher-Stine L; Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
  • Lloyd TE; Barcelona University, Barcelona, Spain.
  • Liewluck T; CIBERER and IDIBAPS, Barcelona, Spain.
  • Naddaf E; Pathology, Neurological Tissue Bank, Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain.
  • Stenzel W; Barcelona University, Barcelona, Spain.
  • Greenberg SA; Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERN-ReCONNET, Hospital Clinic, Barcelona, Spain.
  • Grau JM; Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
  • Selva-O'Callaghan A; Autonomous University of Barcelona, Barcelona, Spain.
  • Milisenda JC; Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
  • Mammen AL; Autonomous University of Barcelona, Barcelona, Spain.
Ann Rheum Dis ; 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38902010
ABSTRACT

OBJECTIVES:

Autoantibodies targeting intracellular proteins are common in various autoimmune diseases. In the context of myositis, the pathologic significance of these autoantibodies has been questioned due to the assumption that autoantibodies cannot enter living muscle cells. This study aims to investigate the validity of this assumption.

METHODS:

Confocal immunofluorescence microscopy was employed to localise antibodies and other proteins of interest in myositis muscle biopsies. Bulk RNA sequencing was used to examine the transcriptomic profiles of 669 samples, including those from patients with myositis, disease controls and healthy controls. Additionally, antibodies from myositis patients were introduced into cultured myoblasts through electroporation, and their transcriptomic profiles were analysed using RNA sequencing.

RESULTS:

In patients with myositis autoantibodies, antibodies accumulated inside myofibres in the same subcellular compartment as the autoantigen. Bulk RNA sequencing revealed that muscle biopsies from patients with autoantibodies targeting transcriptional regulators exhibited transcriptomic patterns consistent with dysfunction of the autoantigen. For instance, in muscle biopsies from patients with anti-PM/Scl autoantibodies recognising components of the nuclear RNA exosome complex, an accumulation of divergent transcripts and long non-coding RNAs was observed; these RNA forms are typically degraded by the nuclear RNA exosome complex. Introducing patient antibodies into cultured muscle cells recapitulated the transcriptomic effects observed in human disease. Further supporting evidence suggested that myositis autoantibodies recognising other autoantigens may also disrupt the function of their targets.

CONCLUSIONS:

This study demonstrates that, in myositis, autoantibodies are internalised into living cells, causing biological effects consistent with the disrupted function of their autoantigen.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ann Rheum Dis Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ann Rheum Dis Año: 2024 Tipo del documento: Article